Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells

Authors: Konrad Steinestel, Stefan Eder, Konstantin Ehinger, Juliane Schneider, Felicitas Genze, Eva Winkler, Eva Wardelmann, Andres J. Schrader, Julie Steinestel

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Metastasis is the survival-determining factor in urothelial carcinoma (UC) of the urinary bladder. The small conductance calcium-activated potassium channel 3 (SK3) enhances tumor cell invasion in breast cancer and malignant melanoma. Since Edelfosine, a glycerophospholipid with antitumoral properties, effectively inhibits SK3 channel activity, our goal was to evaluate SK3 as a potential molecular target to inhibit the gain of an invasive phenotype in UC. SK3 protein expression was analyzed in 208 tissue samples and UC cell lines. Effects of Edelfosine on SK3 expression and intracellular calcium levels as well as on cell morphology, cell survival and proliferation were assessed using immunoblotting, potentiometric fluorescence microscopy, and clonogenic/cell survival assay; furthermore, we analyzed the effect of Edelfosine and SK3 RNAi knockdown on tumor cell migration and invasion in vitro and in vivo. We found that SK3 is strongly expressed in muscle-invasive UC and in the RT112 cellular tumor model. Higher concentrations of Edelfosine have a strong antitumoral effect on UC cells, while 1 μM effectively inhibits migration/invasion of UC cells in vitro and in vivo comparable to the SK3 knockdown phenotype. Taken together, our results show strong expression of SK3 in muscle-invasive UC, consistent with the postulated role of the protein in tumor cell invasion. Edelfosine is able to effectively inhibit migration and invasion of UC cells in vitro and in vivo in an SK3-dependent way, pointing towards a possible role for Edelfosine as an antiinvasive drug to effectively inhibit UC cell invasion and metastasis.
Literature
1.
go back to reference Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41.CrossRefPubMed Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41.CrossRefPubMed
2.
go back to reference Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.CrossRefPubMed Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.CrossRefPubMed
3.
go back to reference Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009–18.CrossRefPubMed Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009–18.CrossRefPubMed
4.
go back to reference Girault A, Haelters JP, Potier-Cartereau M, Chantome A, Jaffres PA, Bougnoux P, et al. Targeting SKCa channels in cancer: potential new therapeutic approaches. Curr Med Chem. 2012;19(5):697–713.CrossRefPubMed Girault A, Haelters JP, Potier-Cartereau M, Chantome A, Jaffres PA, Bougnoux P, et al. Targeting SKCa channels in cancer: potential new therapeutic approaches. Curr Med Chem. 2012;19(5):697–713.CrossRefPubMed
7.
go back to reference Bond CT, Maylie J, Adelman JP. SK channels in excitability, pacemaking and synaptic integration. Curr Opin Neurobiol. 2005;15(3):305–11.CrossRefPubMed Bond CT, Maylie J, Adelman JP. SK channels in excitability, pacemaking and synaptic integration. Curr Opin Neurobiol. 2005;15(3):305–11.CrossRefPubMed
8.
go back to reference Xia X-M, Fakler B, Rivard A, Wayman G, Johnson-Pais T, Keen J, et al. Mechanism of calcium gating in small-conductance calcium-activated potassium channels. Nature. 1998;395(6701):503–7.CrossRefPubMed Xia X-M, Fakler B, Rivard A, Wayman G, Johnson-Pais T, Keen J, et al. Mechanism of calcium gating in small-conductance calcium-activated potassium channels. Nature. 1998;395(6701):503–7.CrossRefPubMed
9.
go back to reference Chantome A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Gueguinou M, et al. Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73(15):4852–61. doi:10.1158/0008-5472.can-12-4572.CrossRefPubMed Chantome A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Gueguinou M, et al. Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73(15):4852–61. doi:10.​1158/​0008-5472.​can-12-4572.CrossRefPubMed
10.
go back to reference Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011;11(8):609–18.CrossRefPubMed Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011;11(8):609–18.CrossRefPubMed
14.
go back to reference Potier M, Chantôme A, Joulin V, Girault A, Roger S, Besson P, et al. The SK3/KCa2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011;162(2):464–79.CrossRefPubMedPubMedCentral Potier M, Chantôme A, Joulin V, Girault A, Roger S, Besson P, et al. The SK3/KCa2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011;162(2):464–79.CrossRefPubMedPubMedCentral
15.
go back to reference Slaton JW, Hampton JA, Selman SH. Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J Urol. 1994;152(5 Pt 1):1594–8.PubMed Slaton JW, Hampton JA, Selman SH. Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J Urol. 1994;152(5 Pt 1):1594–8.PubMed
16.
go back to reference Steinestel J, Cronauer M, Müller J, Al Ghazal A, Skowronek P, Arndt A, et al. Overexpression of p16 (INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One. 2013;8(5):e65189-e.CrossRef Steinestel J, Cronauer M, Müller J, Al Ghazal A, Skowronek P, Arndt A, et al. Overexpression of p16 (INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One. 2013;8(5):e65189-e.CrossRef
17.
go back to reference Innocenti M, Gerboth S, Rottner K, Lai FP, Hertzog M, Stradal TE, et al. Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes. Nat Cell Biol. 2005;7(10):969–76.CrossRefPubMed Innocenti M, Gerboth S, Rottner K, Lai FP, Hertzog M, Stradal TE, et al. Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes. Nat Cell Biol. 2005;7(10):969–76.CrossRefPubMed
18.
go back to reference Steinestel K, Brüderlein S, Lennerz JK, Steinestel J, Kraft K, Pröpper C, et al. Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol Cancer. 2014;13(1):145.CrossRefPubMedPubMedCentral Steinestel K, Brüderlein S, Lennerz JK, Steinestel J, Kraft K, Pröpper C, et al. Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol Cancer. 2014;13(1):145.CrossRefPubMedPubMedCentral
19.
go back to reference Weaver AK, Bomben VC, Sontheimer H. Expression and function of calcium‐activated potassium channels in human glioma cells. Glia. 2006;54(3):223–33.CrossRefPubMedPubMedCentral Weaver AK, Bomben VC, Sontheimer H. Expression and function of calcium‐activated potassium channels in human glioma cells. Glia. 2006;54(3):223–33.CrossRefPubMedPubMedCentral
20.
go back to reference Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.CrossRefPubMed Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.CrossRefPubMed
21.
go back to reference Haller T, Dietl P, Deetjen P, Völkl H. The lysosomal compartment as intracellular calcium store in MDCK cells: a possible involvement in InsP 3-mediated Ca 2+ release. Cell Calcium. 1996;19(2):157–65.CrossRefPubMed Haller T, Dietl P, Deetjen P, Völkl H. The lysosomal compartment as intracellular calcium store in MDCK cells: a possible involvement in InsP 3-mediated Ca 2+ release. Cell Calcium. 1996;19(2):157–65.CrossRefPubMed
22.
go back to reference Isachenko V, Mallmann P, Petrunkina AM, Rahimi G, Nawroth F, Hancke K, et al. Comparison of in vitro-and chorioallantoic membrane (CAM)-culture systems for cryopreserved medulla-contained human ovarian tissue. PLoS One. 2012;7(3):e32549.CrossRefPubMedPubMedCentral Isachenko V, Mallmann P, Petrunkina AM, Rahimi G, Nawroth F, Hancke K, et al. Comparison of in vitro-and chorioallantoic membrane (CAM)-culture systems for cryopreserved medulla-contained human ovarian tissue. PLoS One. 2012;7(3):e32549.CrossRefPubMedPubMedCentral
Metadata
Title
The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells
Authors
Konrad Steinestel
Stefan Eder
Konstantin Ehinger
Juliane Schneider
Felicitas Genze
Eva Winkler
Eva Wardelmann
Andres J. Schrader
Julie Steinestel
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4509-5

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine